• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by AIkido Pharma Inc.

    8/11/23 4:08:19 PM ET
    $AIKI
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AIKI alert in real time by email
    DEFA14A 1 ea183071-defa14a_dominari.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

     

     

     

    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

     

    Filed by the Registrant   ☒
    Filed by a Party other than the Registrant   ☐

     

    Check the appropriate box:

     

    ☐   Preliminary Proxy Statement
    ☐   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐   Definitive Proxy Statement
    ☒   Definitive Additional Materials
    ☐   Soliciting Material under §240.14a-12

     

    DOMINARI HOLDINGS INC.
    (Name of Registrant as Specified In Its Charter)

     

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒   No fee required
    ☐   Fee paid previously with preliminary materials.
    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

    Get the next $AIKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIKI

    DatePrice TargetRatingAnalyst
    10/11/2021$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AIKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dominari Holdings Provides Update on Share Repurchase Program

      NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part

      12/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH)

      NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C

      12/22/22 8:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

      Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita

      11/28/22 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/26/23 6:43:23 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Leadership Updates

    Live Leadership Updates

    See more

    $AIKI
    Financials

    Live finance-specific insights

    See more
    • AIkido Pharma Inc. Appoints New Director, Soo Yu

      New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company.  Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu's background broadens t

      6/10/22 4:15:00 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching

      NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public.  AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00.  As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad

      9/14/21 9:22:00 AM ET
      $AIKI
      $DATS
      Specialty Chemicals
      Consumer Discretionary
      Telecommunications Equipment
      Telecommunications
    • AIkido Pharma Provides Business Update

      NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our

      4/5/21 9:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease

      NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease.  The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system.  This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob

      6/23/21 10:00:00 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on AIkido Pharma with a new price target

      HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00

      10/11/21 6:14:44 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AIkido Pharma Inc.

      SC 13D - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:15:22 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      12/28/23 4:05:18 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)

      SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

      7/6/23 4:30:08 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:33 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/28/23 8:00:36 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)

      4 - Dominari Holdings Inc. (0000012239) (Issuer)

      12/22/23 6:00:41 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary

    $AIKI
    SEC Filings

    See more
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      12/18/23 4:05:35 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Dominari Holdings Inc. (0000012239) (Filer)

      11/13/23 6:05:12 AM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 10-Q filed by AIkido Pharma Inc.

      10-Q - Dominari Holdings Inc. (0000012239) (Filer)

      11/6/23 4:47:02 PM ET
      $AIKI
      Specialty Chemicals
      Consumer Discretionary